Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Saved in:
| Title: | Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. |
|---|---|
| Authors: | Hengeveld PJ; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands., Schilperoord-Vermeulen J; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands., van der Klift MY; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands., Dubois JMN; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., Kolijn PM; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands., Kavelaars FG; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Rijken M; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Dobber JA; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., Nasserinejad K; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Kersting S; Department of Hematology, Haga Hospital, The Hague, The Netherlands., Westerweel PE; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Kater AP; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands., Langerak AW; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands. m-d.levin@asz.nl. |
| Source: | Blood cancer journal [Blood Cancer J] 2023 Jul 04; Vol. 13 (1), pp. 102. Date of Electronic Publication: 2023 Jul 04. |
| Publication Type: | Letter; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37400508 AccessLevel: 2 PubType: Report PubTypeId: report PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hengeveld+PJ%22">Hengeveld PJ</searchLink>; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Schilperoord-Vermeulen+J%22">Schilperoord-Vermeulen J</searchLink>; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Klift+MY%22">van der Klift MY</searchLink>; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Dubois+JMN%22">Dubois JMN</searchLink>; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Kolijn+PM%22">Kolijn PM</searchLink>; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Kavelaars+FG%22">Kavelaars FG</searchLink>; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Rijken+M%22">Rijken M</searchLink>; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Dobber+JA%22">Dobber JA</searchLink>; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Nasserinejad+K%22">Nasserinejad K</searchLink>; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Kersting+S%22">Kersting S</searchLink>; Department of Hematology, Haga Hospital, The Hague, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Westerweel+PE%22">Westerweel PE</searchLink>; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Department of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Langerak+AW%22">Langerak AW</searchLink>; Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands. m-d.levin@asz.nl. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2023 Jul 04; Vol. 13 (1), pp. 102. <i>Date of Electronic Publication: </i>2023 Jul 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Letter; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37400508 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41408-023-00870-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 102 Titles: – TitleFull: Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hengeveld PJ – PersonEntity: Name: NameFull: Schilperoord-Vermeulen J – PersonEntity: Name: NameFull: van der Klift MY – PersonEntity: Name: NameFull: Dubois JMN – PersonEntity: Name: NameFull: Kolijn PM – PersonEntity: Name: NameFull: Kavelaars FG – PersonEntity: Name: NameFull: Rijken M – PersonEntity: Name: NameFull: Dobber JA – PersonEntity: Name: NameFull: Nasserinejad K – PersonEntity: Name: NameFull: Kersting S – PersonEntity: Name: NameFull: Westerweel PE – PersonEntity: Name: NameFull: Kater AP – PersonEntity: Name: NameFull: Langerak AW – PersonEntity: Name: NameFull: Levin MD IsPartOfRelationships: – BibEntity: Dates: – D: 04 M: 07 Text: 2023 Jul 04 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2044-5385 Numbering: – Type: volume Value: 13 – Type: issue Value: 1 Titles: – TitleFull: Blood cancer journal Type: main |
| ResultId | 1 |
